Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin plus rivaroxaban versus rivaroxaban alone for prevention of venous stent thrombosis in post-thrombotic syndrome
2019-001723-12Phase 2Terminated
- Sponsor
- University Hospital Zurich
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in post-thrombotic syndrome (PTS) and stent thrombosis comparing Aspirin plus rivaroxaban with Rivaroxaban alone (2 arms). Primary endpoint: Primary patency rate at 6 months. Started Jan 2020; status: terminated.
02
Drugs
aspirinrivaroxaban
03
Conditions
post-thrombotic syndrome (PTS)stent thrombosis
Beyond the preview
Go deeper on 2019-001723-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001723-12.